{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir&page=6", "query": { "intervention": "Raltegravir", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 125, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T15:25:49.516Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00711009", "title": "Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Infection" ], "interventions": [ { "name": "lopinavir/ritonavir (LPV/r)", "type": "DRUG" }, { "name": "emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)", "type": "DRUG" }, { "name": "raltegravir (RAL)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 206, "start_date": "2008-07", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2012-02-14", "last_synced_at": "2026-10-17T15:25:49.516Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Atlantis", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711009" }, { "nct_id": "NCT01234116", "title": "Post-Exposure Prophylaxis in Health Care Workers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "emtricitabine/tenofovir disoproxil fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2011-02", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-17T15:25:49.516Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234116" }, { "nct_id": "NCT01214759", "title": "Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Truvada", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2011-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-10-17T15:25:49.516Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01214759" }, { "nct_id": "NCT01568892", "title": "Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Dolutegravir 50 mg twice daily", "type": "DRUG" }, { "name": "Dolutegravir placebo twice daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2012-04-18", "completion_date": "2013-12-16", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-17T15:25:49.516Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01568892" }, { "nct_id": "NCT01896921", "title": "Switch to Maraviroc + Integrase Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Switch to Maraviroc + Raltegravir or Dolutegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 7, "start_date": "2013-09", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-10-17T15:25:49.516Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896921" }, { "nct_id": "NCT01525628", "title": "Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "midazolam", "type": "DRUG" }, { "name": "BI 201335", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "tolbutamide", "type": "DRUG" }, { "name": "pegylated interferon", "type": "DRUG" }, { "name": "BI 207127", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 72, "start_date": "2012-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-06-10", "last_synced_at": "2026-10-17T15:25:49.516Z", "location_count": 5, "location_summary": "La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525628" }, { "nct_id": "NCT00440271", "title": "SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "tipranavir", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" }, { "name": "Optimized Background Regimen (OBR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2007-02", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-10-17T15:25:49.516Z", "location_count": 16, "location_summary": "Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00440271" }, { "nct_id": "NCT00740064", "title": "Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir and Abacavir/Lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Denver Infectious Disease Consultants, PLLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-05", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2009-01-28", "last_synced_at": "2026-10-17T15:25:49.516Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Denver, Colorado • Santa Fe, New Mexico", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Santa Fe", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00740064" }, { "nct_id": "NCT00762892", "title": "Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir and truvada", "type": "DRUG" }, { "name": "Atazanavir, Norvir and Truvada", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2009-01", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2015-01-05", "last_synced_at": "2026-10-17T15:25:49.516Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00762892" }, { "nct_id": "NCT01780831", "title": "Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 52, "start_date": "2014-01-28", "completion_date": "2018-04-20", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-10-17T15:25:49.516Z", "location_count": 8, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01780831" } ] }